Following on from our
earlier article on patent term extension (PTE) for
pharmaceutical substances, three related decisions issued by the
Australian Patent Office provide guidance on the requirements and
potential pitfalls when seeking an extension of term.
Criteria for eligibility and
necessary document
As noted in our previous article, as
set out by section 70 of the Patents Act 1990, a patent is
eligible for PTE i) where the claims of the patent encompass:
- Pharmaceutical substance(s) per se; or
- Pharmaceutical substance(s) produced by recombinant DNA
technology
and ii) where that pharmaceutical
substance is included in goods which have received regulatory
approval at least five years following the effective date of the
patent. The PTE application must be made in the
"prescribed manner" which includes providing evidence to
show that the goods containing the substance are currently included
in the Australian Register of Therapeutic Goods (ARTG) and